Weston Kightlinger has a thing for difficult problems in protein engineering. His last venture, SwiftScale Biologics, caught the eye of National Resilience, which acquired it in late 2021. Now he's back with something arguably more ambitious: a Palo Alto startup trying to make antibody-drug conjugates—those finicky, high-stakes cancer therapeutics—actually work the way oncologists wish they would.
Ridge Biotechnologies emerged from stealth in September with $25 million in seed funding, led and incubated by Sutter Hill Ventures with participation from Overlap Holdings. The pitch? Use machine learning to crack longstanding puzzles in precision drug design, particularly around ADCs, where getting uniform drug loading and tumor-specific activation remains maddeningly hard to scale.
It's a crowded field. But Ridge has assembled the kind of advisory bench that makes competitors take notice—starting with Carolyn Bertozzi, the Stanford chemist who won the 2022 Nobel Prize for bioorthogonal chemistry, the very foundation underlying click chemistry in ADC design. She's joined by Michael Jewett (also Stanford), Sangeeta Bhatia of MIT and the Howard Hughes Medical Institute, Gabriel Kwong at Georgia Tech, Hans Wandall from the University of Copenhagen, and Vesna Mitchell, who previously worked at Codexis.
That roster signals intent. Whether it translates to breakthroughs is the $25 million question.
Three Platforms, One Wager
Ridge's approach hinges on three interlocking product lines, each targeting a specific bottleneck in conjugate design.
NativeLink enables site-specific conjugation of proteins and peptides without the headache of altering cell lines or engineering in non-standard amino acids. The result: homogeneous ADCs, antibody-oligonucleotide conjugates, radiopharmaceuticals, and peptide-drug conjugates with stable linkages. Homogeneity matters because inconsistent drug loading can mean unpredictable efficacy and toxicity—a problem that has haunted ADCs for years.
ProTrigger leans harder on AI, designing protease-responsive linkers that release or activate payloads only in target tissues. The goal is to sidestep off-tumor toxicity and unlock targets that internalize poorly, expanding the range of what ADCs can hit. It's ambitious. Protease gradients in tumors vary wildly, and predicting linker behavior in vivo has tripped up more than a few well-funded efforts.
The third platform, Catalytic Medicines, focuses on precision enzyme therapeutics engineered to reach abundant or hard-to-drug targets through what the company calls "differentiated mechanisms." Details remain sparse—perhaps deliberately so at this stage.
Ridge says it's already partnered with a "leading ADC-focused biotech" using ProTrigger and NativeLink, though the company declined to name names in its September announcement. A collaboration this early suggests somebody with deep pockets liked what they saw in the data.
Sutter Hill's Latest Biotech Gamble
Sutter Hill Ventures, known for building companies from scratch rather than simply writing checks, incubated Ridge and brought in Keith Loebner as director and founding investor. Kightlinger, the CEO, spent time leading cell-free protein synthesis at Resilience after the SwiftScale acquisition—experience that likely informed Ridge's focus on manufacturing-friendly conjugation methods.
Cell-free systems have their evangelists, though they've yet to fully break into mainstream therapeutic production. Whether Kightlinger can bridge that gap here remains to be seen.
The company filed trademarks for "Ridge Bio" and "ProTrigger" on September 5, 2025, and listed between 11 and 50 employees on LinkedIn from January through April 2026. It's also hunting for a chief business officer with deep ties across pharma, biotech, CROs, and CDMOs—a signal that partnerships, not just platform development, will drive near-term growth.
Landing in a Volatile Market
Ridge's September 2025 seed round of $25 million lands it in the middle of a bifurcated funding environment for AI-driven biotech. Fathom (formerly Atommap) pulled in $47 million for its Series A in April 2026. Scala Biodesign closed a $16 million Series A in March for antibody and protein design. And Stipple Bio—another computational biology play—emerged with a whopping $100 million Series A the same year, underscoring just how wide the valuation range has become.
Ridge's raise looks measured by comparison, which could mean either disciplined growth or a tougher road ahead to compete with better-capitalized rivals. Investors are clearly still willing to bet on computational platforms in drug discovery, but the bar for demonstrating real-world impact has risen sharply since the frenzy of 2020 and 2021.
The company plans to exhibit at the BIO International Convention in 2026, a venue where early-stage biotechs often scout for pharma partnerships. If Ridge can convert its academic firepower and early collaboration into broader deals, it might justify the Nobel-sized expectations hanging over it.
For now, it's a promising seed round with a lot left to prove. ADCs are notoriously difficult. And promising platforms, even those blessed by laureates, still have to survive the messy reality of clinical development.
